Volume 94 Issue 43 | p. 25
Issue Date: October 31, 2016

Cover Stories

10 Start-Ups to Watch

Young companies powered by chemistry
Department: Business
Keywords: cover story, start-ups, biotech, 3D printing, pesticides
[+]Enlarge
Credit: Will Ludwig/C&EN/Shutterstock
A graphic with Snap Circuits and logo that reads 10 Start-ups to watch.
 
Credit: Will Ludwig/C&EN/Shutterstock

Any seasoned entrepreneur knows that starting a company takes much more than just a great idea. Creating a successful business is a careful exercise in timing, planning, and tenacity. Like setting up a circuit, all the right pieces need to snap into place in order for the lights to come on. The right scientific minds need to encounter the right business minds at a time when the world is ready for—and ready to pay for—a particular innovation.

In the following pages, C&EN is, for the second year, telling the stories of 10 young companies that have managed to bring all the right pieces together. Working across the chemical enterprise, they were selected by our business reporters because they reflect the way chemistry is at the foundation of so many important technological advances.

Several of the firms are addressing some of the world’s most recalcitrant scientific problems, including neglected disease, electronics miniaturization, and energy conservation. Others are finding ways to bring to reality the things we have so far only imagined—a television that can rolled up like a sheet of paper, for example. Most are the product of years of academic research that has finally been pulled out of the lab.

As always, we remind readers of the outsized failure rate for start-ups. Far more fold than flourish. That said, we think these companies have a good shot at beating the odds. 

Know a start-up we should consider for next year's list? Nominate it here: cenm.ag/startupnom

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society
Comments
Girish Malhotra  (November 6, 2016 5:59 PM)
Pharmaceutical (API) do not have volume per company to go continuous. Formulations could have done it 60+ plus years ago. Didn't. Can't justify investment with the current business model.
Continuus pharmaceutical has to review its sales pitch.
Leave A Comment